Answers are grounded in this paper and cite their sources.
Therapeutic system forms of nitroglycerin are being developed and undergoing clinical evaluation, though no data have yet been published. Current technological methods make transdermal systems of reasonable size practicable for drugs active at a daily parenteral dose of 10 mg or less.25 Development of such dosage forms should complement the traditional route for advancement of treatment-namely, the new chemical structure.26 The therapeutic system will broaden the charter for new drug seekers, for they now can think in terms of drugs with short biological half lives or narrow therapeutic indices.
No takes yet. Share an insight, caveat, or question.
S. Lock (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: